Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

The post discusses using ImageJ software to objectively track hair regrowth progress. The user is treating Androgen alopecia with dutasteride and minoxidil.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Considering adding Low Level Laser Therapy (LLLT) to a hair loss prevention regimen; discussing the effectiveness of LLLT, and evaluating double-blind random-controlled trials that have been conducted on laser combs.

The user is asking for opinions on low level laser light therapy for hair growth and thickening. They have been using it for a year but haven't seen significant results, attributing any regrowth to topical minoxidil.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

Ultrasound imaging can non-invasively detect active and inactive hair follicles, inflammation, and fibrosis, potentially reducing unnecessary biopsies. It may help assess hair growth potential and diagnose scalp issues, but some users believe in trying treatments regardless of ultrasound results.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation is about a person rapidly losing hair and seeking information on the availability of a new treatment called scube3, as they have experienced side effects from current treatments like Minoxidil and finasteride. They are hoping scube3 will be approved soon as they believe it's their only remaining option.

The user is considering buzzing their long hair to better assess the effects of finasteride, which they have been using for over two months, and is concerned about maintaining their unique appearance. They are also curious if dyeing short hair could cause any issues.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

A user's plan to use Zix and topical finasteride (5AR inhibitors) for hair loss, followed by blood testing before/after. The user has suggested creating a fund to cover part of the cost of their blood tests. Replies to their post discuss the effectiveness of the treatments.

The user plans to use a "nuclear protocol" for hair improvement, including topical minoxidil 12.5%, topical finasteride 0.1%, and tretinoin 0.05%, with microneedling once a week. They have seen improvements with minoxidil and are seeking opinions on their approach to achieve thicker hair.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.

The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user experienced scalp irritation from a Finasteride and Minoxidil spray and serum. They are considering switching to foam, oral treatments, or another provider.

The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.